The following adverse effects were reported in patients receiving semaglutide injection or oral tablets across all clinical trials and at incidences higher than with placebo: nausea (11% to 44%), vomiting (5% to 24%), diarrhea (8.5% to 30%), abdominal pain (5.7% to 20%), abdominal distention (2% to 7%), constipation (3.1% to 24%), dyspepsia (0.6% to 9%), decreased appetite (6% to 9%), eructation (0.6% to 7%), flatulence (0.4% to 6%), gastroesophageal reflux disease (1.5% to 5%), gastroenteritis (4% to 6%), and gastritis (0.4% to 4%)
Other types of kidney problems include acute kidney injury, chronic kidney disease, and kidney failure or end stage renal disease
Bulletin of Experimental Biology and Medicine, 2003
Recovery is generally driven by surgical technique, structured rehabilitation, pain and swelling management, and progressive loading
It is advisable to avoid layering multiple copper-containing products within the same regimen, as cumulative exposure may elevate copper levels beyond what is considered safe for topical use
How Is GHK-Cu Administered